Edition:
India

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

3.04USD
23 Feb 2018
Change (% chg)

$0.06 (+2.01%)
Prev Close
$2.98
Open
$3.06
Day's High
$3.13
Day's Low
$2.99
Volume
516,414
Avg. Vol
906,452
52-wk High
$6.96
52-wk Low
$0.67

Latest Key Developments (Source: Significant Developments)

Mannkind Q3 loss per share $0.31
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Mannkind Corp ::Mannkind Corporation reports 2017 third quarter financial results.Q3 loss per share $0.31.  Full Article

Mannkind restructures near-term debt obligations
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Mannkind Corp ::Mannkind restructures near-term debt obligations.Mannkind Corp - ‍extended maturity of $10 million of deerfield facility to Jan 15, 2018 and allowed for such principal to be converted into common stock​.Mannkind - ‍new 5.75 pct convertible senior subordinated exchange notes due 2021, common stock to be issued.Mannkind - ‍new 5.75 pct notes due 2021, common stock to be issued in exchange for existing convertible senior subordinated exchange notes due 2018​.Mannkind - ‍2021 notes will bear interest at rate of 5.75 pct per year on principal amount, payable semiannually​.Mannkind - ‍2021 notes will mature on october 23, 2021​.Mannkind - facility agreement amended to provide that deerfield may convert principal due into aggregate of up to 4 million shares of co's stock​.  Full Article

Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa)
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Biomm Sa ::Mannkind and Biomm submit registration dossier to Brazilian Health Regulatory Agency (anvisa).Mannkind Corp - co, Biomm SA announce submission of registration dossier to anvisa, seeking approval of afrezza inhalation powder in Brazil​.  Full Article

Securities Class Action Against MannKind Dismissed
Thursday, 25 Aug 2016 

Mannkind Corp : U.S. District court for central district of California has dismissed class action that was pending against Mannkind and two of executives .Says court granted defendants' motion to dismiss plaintiffs' amended class action complaint without leave to amend.  Full Article

Mannkind Corporation reports 2016 Q2 financial results
Tuesday, 9 Aug 2016 

Mannkind Corp : Mannkind Corporation reports 2016 second quarter financial results .Net loss for Q2 of 2016 was $30.0 million, or $0.07 per share.  Full Article

Mannkind reports Q1 net loss $0.06 per share
Tuesday, 10 May 2016 

Mannkind Corp : Net loss for Q1 of 2016 was $24.9 million, or $0.06 per share .Q1 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-David Kendall Joins MannKind As Chief Medical Officer

* MANNKIND CORP - MOST RECENTLY, KENDALL SERVED AS RESEARCH PHYSICIAN AND VICE PRESIDENT OF GLOBAL MEDICAL AFFAIRS FOR LILLY DIABETES​ Source text for Eikon: Further company coverage: